CL2023002414A1 - Métodos para usar anticuerpos que reconocen tau - Google Patents
Métodos para usar anticuerpos que reconocen tauInfo
- Publication number
- CL2023002414A1 CL2023002414A1 CL2023002414A CL2023002414A CL2023002414A1 CL 2023002414 A1 CL2023002414 A1 CL 2023002414A1 CL 2023002414 A CL2023002414 A CL 2023002414A CL 2023002414 A CL2023002414 A CL 2023002414A CL 2023002414 A1 CL2023002414 A1 CL 2023002414A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- methods
- tau
- recognize tau
- recognize
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 102000057063 human MAPT Human genes 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 102000013498 tau Proteins Human genes 0.000 abstract 1
- 108010026424 tau Proteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona métodos para tratar taupatías tales como enfermedad de Alzheimer con anticuerpos que se unen a tau humana. Los anticuerpos inhiben o retrasan patologías asociadas con tau y deterioro sintomático relacionado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163149359P | 2021-02-14 | 2021-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002414A1 true CL2023002414A1 (es) | 2024-02-23 |
Family
ID=82837931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002414A CL2023002414A1 (es) | 2021-02-14 | 2023-08-14 | Métodos para usar anticuerpos que reconocen tau |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220267426A1 (es) |
| EP (1) | EP4291234A1 (es) |
| JP (1) | JP2024506391A (es) |
| KR (1) | KR20230146056A (es) |
| CN (1) | CN117136073A (es) |
| AU (1) | AU2022219986A1 (es) |
| BR (1) | BR112023016271A2 (es) |
| CA (1) | CA3208191A1 (es) |
| CL (1) | CL2023002414A1 (es) |
| IL (1) | IL305161A (es) |
| MX (1) | MX2023009470A (es) |
| TW (1) | TW202246320A (es) |
| WO (1) | WO2022174026A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2758433B1 (en) * | 2011-09-19 | 2017-10-18 | Axon Neuroscience SE | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
| KR101582852B1 (ko) * | 2012-05-24 | 2016-01-07 | 서울대학교 산학협력단 | 타우 단백질 매개 신경 퇴행성 질환 치료제 |
| WO2017191560A1 (en) * | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| WO2018204546A2 (en) * | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
| BR112021016947A2 (pt) * | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
| EP3725370A1 (en) * | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| US20230075314A1 (en) * | 2019-04-29 | 2023-03-09 | Voyager Therapeutics, Inc. | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF |
-
2022
- 2022-02-11 TW TW111105169A patent/TW202246320A/zh unknown
- 2022-02-11 IL IL305161A patent/IL305161A/en unknown
- 2022-02-11 MX MX2023009470A patent/MX2023009470A/es unknown
- 2022-02-11 CN CN202280027834.4A patent/CN117136073A/zh active Pending
- 2022-02-11 WO PCT/US2022/016105 patent/WO2022174026A1/en active Application Filing
- 2022-02-11 AU AU2022219986A patent/AU2022219986A1/en active Pending
- 2022-02-11 CA CA3208191A patent/CA3208191A1/en active Pending
- 2022-02-11 JP JP2023548895A patent/JP2024506391A/ja active Pending
- 2022-02-11 EP EP22753402.1A patent/EP4291234A1/en active Pending
- 2022-02-11 BR BR112023016271A patent/BR112023016271A2/pt unknown
- 2022-02-11 KR KR1020237031163A patent/KR20230146056A/ko unknown
- 2022-02-14 US US17/671,420 patent/US20220267426A1/en not_active Abandoned
-
2023
- 2023-08-14 CL CL2023002414A patent/CL2023002414A1/es unknown
- 2023-08-28 US US18/456,932 patent/US20240018226A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023016271A2 (pt) | 2023-11-14 |
| JP2024506391A (ja) | 2024-02-13 |
| EP4291234A1 (en) | 2023-12-20 |
| KR20230146056A (ko) | 2023-10-18 |
| AU2022219986A1 (en) | 2023-08-31 |
| MX2023009470A (es) | 2023-09-21 |
| US20220267426A1 (en) | 2022-08-25 |
| WO2022174026A1 (en) | 2022-08-18 |
| TW202246320A (zh) | 2022-12-01 |
| CA3208191A1 (en) | 2022-08-18 |
| US20240018226A1 (en) | 2024-01-18 |
| CN117136073A (zh) | 2023-11-28 |
| IL305161A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202000086A (es) | Agentes vinculantes de psma y usos de los mismos | |
| CO2017013356A2 (es) | Anticuerpos de factor xi | |
| CO2021011140A2 (es) | Anticuerpos que reconocen tau | |
| CL2019000488A1 (es) | Anticuerpos de anti-tim-3. | |
| CO2021011644A2 (es) | Anticuerpos que reconocen tau | |
| CO2021001893A2 (es) | Anticuerpos anti-gdf15, composiciones y métodos de uso | |
| CO2021007370A2 (es) | Anticuerpos que reconocen tau | |
| BR112019022906A2 (pt) | Anticorpos que reconhecem tau | |
| CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
| CL2019001129A1 (es) | Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y. | |
| CU24538B1 (es) | Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7 | |
| NI201900086A (es) | Anticuerpos humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo. | |
| AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
| CO2019003759A2 (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos | |
| ECSP21053104A (es) | Moduladores de la expresión de hsd17b13 | |
| MX2020009130A (es) | Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. | |
| UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
| CL2019003485A1 (es) | Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909) | |
| AR122736A1 (es) | Anticuerpos que reconocen sortilina | |
| CL2023002414A1 (es) | Métodos para usar anticuerpos que reconocen tau | |
| PE20210418A1 (es) | Moleculas de anticuerpo de componente de complemento 5 y sus usos | |
| ES1264174Y (es) | Estuche para lentes de exploracion oftalmologica | |
| ES1235378Y (es) | Dispositivo portaobjetos para estudio de nematodos | |
| JP1733987S (ja) | 口紅用ケース | |
| JP1747219S (ja) | 皮革地 |